Stenotrophomonas, Burkholderia, and Achromobacter species are all ubiquitous environmental organisms found in water, soil, the rhizosphere, and in and on plants. They have a worldwide distribution. SENTRY data from 1997 to 2003 identified 221,084 bacterial isolates, including 11.5% that were nonenteric GNB, of which Pseudomonas and Acinetobacter species accounted for the majority (82.7%). 13 Of the remaining nonenteric GNB isolated, 3,509 isolates were analyzed, of which S. maltophilia accounted for 59.2%, B. cepacia complex 7.7%, and Achromobacter species 6.7%. 13 Amongst cancer patients at the MD Anderson Cancer Centre, 14 the incidence of S. maltophilia had increased over time, accounting for the 5th most common Gram-negative bacterial isolate. In tropical Australia, bacteremia cases from 2000 to 2010 (over 4,500 cases), S. maltophilia accounted for 1.6% of cases; Achromobacter species 0.2%; and B. cepacia complex was not identified.
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The proportion of CF patients colonized with traditional pathogens has largely remained stable over time, with P. aeruginosa isolated in 60 to 80% of patients, and methicillin-sensitive Staphylococcus aureus in 30 to 60%, while the prevalence of B. cepacia complex remains low (3-5%) with a declining incidence. 16, 17 There is, however, an increasing prevalence of S. maltophilia (4-15%), A. xylosoxidans (3-8%), nontuberculous mycobacteria (5-13%), and methicillinresistant S. aureus (17.2%). 16, 17 In a French regional CF center, over 5,000 sputa were collected from 300 CF patients. The incidence of Pseudomonas was 59%, S. maltophilia 18.9%, B. cenocepacia 13.8%, and A. xylosoxidans 6.9%. Coinfection with two or more of these pathogens was noted to be common. 10 In a multicenter study from Australia and New
Zealand, CF patients colonized with B. cepacia complex were investigated. The authors identified B. multivorans in 29.3% and B. cenocepacia in 45.7%, with some geographic variability. 18 Some CF centers in Australia are dominated instead by B.
multivorans (A.Y. Peleg, written personal communication, July 2014). Multilocus sequence typing scheme has demonstrated that several different Achromobacter species and genogroups can infect patients with CF, although less is known about the possible differences in tropism and pathogenicity between the different species.
11,12,19
Person-to-person transmission of these multidrug-resistant pathogens, especially among CF patients, remains a concern. Unlike B. cepacia complex, where evidence for cross-transmission is well reported, 20 less is known for S. maltophilia and A. xylosoxidans. However, case reports have documented incidences of patient cross-transmission.
10,21,22
All three organisms are capable of causing a variety of infections, including bacteremia, pneumonia, meningitis, urinary tract infections, and nosocomial infections from contaminated environmental sources (e.g., medications, nebulizers, dialysis fluids, saline solution, disinfectants, and contact lens fluid) have been reported. A major virulence factor of these organisms is their ability to produce and survive within biofilms. [23] [24] [25] [26] [27] Biofilm production is associated with resistance to environmental factors by promoting intimate attachment to surfaces, resistance to phagocytic activity and other host immune factors, shielding from antimicrobial activity and enhanced spread across surfaces via bacterial motility. In polymicrobial infections, interspecies interactions have been demonstrated such that different species within the same biofilm can respond to each other's signaling systems and provide survival advantages to the entire polymicrobial community.
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Beyond Human Pathogens B. cepacia complex, S. maltophilia, and A. xylosoxidans share many beneficial environmental effects (see ►Fig. 2), although B. cepacia complex is recognized as a pathogen of onions. These organisms produce antimicrobial compounds that protect plants, cause disease in nematodes, and generate factors that promote plant growth. They also have the ability to degrade a wide variety of compounds, including pollutants and heavy metals, enabling these organisms to be effective agents of soil bioremediation and phytoremediation.
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However, the concern to human health is whether the agricultural use of these organisms may present a risk as reservoirs for antibiotic resistance genes. Their ability to multiply in the soil and rhizosphere of plants may be reason enough to consider restricting plants from high-risk patient groups within hospitals (e.g., immunocompromised or CF wards).
34-36

Identification and Antibiotic Susceptibility Testing
All three organisms have similar growth requirements, can have a similar appearance on standard media, and all can be potentially misidentified as each other and as Pseudomonas species. ►Table 2 outlines the basic microbiological characteristics of these organisms. Automated identification using 
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Modern laboratory identification techniques, such as matrixassisted laser desorption ionization, time-of-flight mass spectrometry (MALDI-TOF MS) appears to identify and discriminate these organisms well, even with specimens from CF patients. [41] [42] [43] The ability for current versions of MALDI-TOF MS instruments to routinely discriminate between the species within the B. cepacia complex requires further work, but importantly does appear to accurately identify B. cenocepacia. 44 When compared with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis of the recA gene, the Microflex LT MALDI-TOF (Bruker Daltonics GmbH, Leipzig, Germany), under the control of the FlexControl 3.0 software (Bruker Daltonics GmbH) and analyzed by Biotyper 2.0 software (Bruker Daltronics GmbH), produced corresponding discriminatory results, although only the PCR-RFLP method provided a fine discrimination into two lineages (IIIA and IIIB).
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A remarkable feature common to these three organisms is the vast array of intrinsic and acquired mechanisms of antibiotic resistance. Intrinsic β-lactamases, a wide range of efflux pump systems, enzymatic modifications, changes in the outer membrane and target site modification are just several of the mechanisms harbored by these organisms. ►Table 3 outlines these mechanisms in more detail, which may or may not be present in every isolate. Importantly, however, is the ability of these organisms to acquire new resistance determinants (e.g., Sul1 integron that causes trimethoprim-sulfamethoxazole resistance in S. maltophilia) and to rapidly induce resistance (e.g., with the use of fluoroquinolones).
Intrinsic antibiotic resistance patterns in S. maltophilia, B. cepacia complex, and A. xylosoxidans are important for physicians to consider when deciding on empiric therapy. Furthermore, this information assists clinical microbiology laboratories with antibiotic susceptibility testing and the CLSI provides clinical breakpoints for B. cepacia complex and recommends first-line testing of trimethoprimsulfamethoxazole, and second line testing of ticarcillinclavulanate, ceftazidime, meropenem, minocycline, levofloxacin, and chloramphenicol. In contrast, EUCAST recently tried to address their lack of clinical breakpoints for B. cepacia complex, however, determined that there was no evidence to describe a relationship for minimum inhibitory concentration (MIC) and outcome, and were unable to provide guidance. They describe the MIC distributions for relevant antimicrobials to be wide and that susceptibility testing was not reproducible using a routine methodology (i.e., MIC determination by the gradient strip method). A Cochrane review 49 in September 2012 also concluded with similar findings, highlighting that they did not find any randomized controlled trials that compared treatments for exacerbations in CF patients who were infected with B. cepacia complex. They concluded that no conclusions could be drawn from their review and clinicians should continue to assess each patient individually, taking into account in vitro antibiotic susceptibility data, previous clinical responses and their own experience. It should be noted that EUCAST consider B. cepacia complex to be intrinsically resistant to ticarcillin-clavulanate but not piperacillin-tazobactam, while in comparison, CLSI reports intrinsic resistance to piperacillin-tazobactam, do not list ticarcillin-clavulanate in their intrinsic resistance appendix, and do provide clinical breakpoints. Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species Abbott, Peleg 105
Relating to A. xylosoxidans, EUCAST does not provide specific guidance beyond their nonspecies-related breakpoints. CLSI provides clinical breakpoints under the section "Other Non-Enterobacteriaceae," although their specific relevance to A. xylosoxidans is debatable.
Management of Infections
The first challenge regarding management is to establish the clinical significance of culturing one of these nonfermenters from a clinical specimen. This question is largely irrelevant if these organisms are identified from sterile sites (e.g., cerebrospinal fluid, blood, and joint aspiration), but when they are identified either alone or with other organisms from nonsterile sites (e.g., sputum, wound swabs, and urine cultures), their role in disease may be difficult to ascertain. However, the repeated isolation of these organisms in the context of clinical disease or in unwell patients, antimicrobial therapy directed against these nonfermenters is often warranted. For example, A. xylosoxidans can cause a level of inflammation similar to P. aeruginosa in chronically infected CF patients and therefore should be treated accordingly.
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Recommendations on specific antibiotic agents for treatment are difficult given the lack of reproducible susceptibility results and minimal clinical data. The fact that these organisms are also frequently part of a mixed infection, especially when it comes to pulmonary involvement, adds to the complexity of management. Reported rates of in vitro antibiotic resistance are very broad depending on patient type and location (see ►Table 5). In general, isolates from CF patients demonstrate higher rates of resistance than those found in other patient groups.
The suggested first-and second-line agents for treatment, as well as combination therapy options are outlined in ►Table 6. Individual susceptibility results, patient allergy, and other concurrent conditions will also influence the choice of agent.
S. maltophilia
Trimethoprim-sulfamethoxazole remains the first-line therapy for S. maltophilia. On the basis of in vitro pharmacodynamics modelling and the bacteriostatic action of trimethoprim-sulfamethoxazole, it is recommended that a higher dose be used (daily dose of 15 mg per kg of the trimethoprim component, split 6 to 8 hourly), 51, 52 which is more similar to the dose chosen for the treatment of Pneumocystis jirovecii pneumonia. In the setting of trimethoprimsulfamethoxazole resistance, second line agents are available and are often used in combination (see ►Table 6). 53 S. maltophilia is inherently resistant to carbapenems, and in fact, use of this class of antibiotic often selects for S. maltophilia in patients who are heavily immunosuppressed (e.g., 62 In contrast to S. maltophilia, B. cepacia complex are often sensitive to meropenem, which is another first-line therapy, but are inherently resistant to polymyxin and colistin. Tigecycline demonstrates poor activity against B. cepacia complex owing to drug efflux, although minocycline maintains activity. 16, [63] [64] [65] Combination therapy is often used for patients who are more severely unwell, and includes double and triple combinations of first-and second-line agents (see ►Table 6).
The main alternative therapeutic agents beyond trimethoprim-sulfamethoxazole include ceftazidime and meropenem, either alone or in combination, or with other antimicrobial agents. 66 The role of penicillins, namely, piperacillin-tazobactam and ticarcillin-clavulanate remains controversial given the different intrinsic resistance reports between EUCAST and CLSI, as previously mentioned. Inhaled tobramycin has the potential to achieve high pulmonary concentrations to inhibit B. cepacia isolates, despite widespread resistance reported. 67, 68 As mentioned, CF patients proceeding to lung transplantation, who are colonized or infected with B. cepacia complex (particularly with B. cenocepacia) are at high risk for a poor outcome, manifested by an overwhelming "cepacia syndrome." 6, 7 The highest risk for this is within 3months following transplant and many lung transplant centers around the world have B. cenocepacia as an absolute contraindication to transplant. If transplantation is performed in the setting of B. cepacia complex colonization or infection, aggressive combination (double and triple) therapy is often used perioperatively.
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A. xylosoxidans
Less is known about the optimal therapy for Achromobacter spp. In addition to the recognized intrinsic antibiotic resistance patterns, acquired resistance is also widely reported. Given the limitations of the clinical microbiology laboratory to interpret antimicrobial susceptibility results, close communication between the treating doctors and the laboratory is required. The most active agents are piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole, whereas ceftazidime is more active than cefepime.
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Tetracyclines (e.g., minocycline) have variable activity and may be vulnerable to a multidrug efflux pump. 73 Although specifically for tigecycline, an MIC 90 of 4 mg/L has been reported in CF patients, suggesting Achromobacter to be a poor target for therapy with tigecycline. 71 Aminoglycosides, fluoroquinolones, fosfomycin, and aztreonam all have poor activity. Multidrug-resistant phenotypes and carbapenemase-producing isolates have been reported, especially for the CF patient population, further complicating therapeutic options. 10, 26, 74 Combination therapy has been recommended for the treatment of A. xylosoxidans pulmonary exacerbations in CF. 75 Although the use of concurrent inhaled antibiotics, such as inhaled colistin, could also be considered.
71,76,77
Conclusions S. maltophilia, B. cepacia complex, and A. xylosoxidans are remarkable organisms with the ability to live and thrive in hostile environments, including withstanding antibiotic treatment. The widespread use of fluoroquinolones, aminoglycosides, and broad-spectrum β-lactam antimicrobials has created the perfect niche for these opportunistic pathogens. Coinfection with Pseudomonas species, interspecies quorumsensing and survival within biofilms create unique therapeutic challenges. Successful treatment requires a greater understanding of the clinical consequences of infections with these organisms, together with their innate microbiological characteristics and antimicrobial resistance patterns. At this stage, more clinical data are required to assist with treatment recommendations, and future research should focus on the role of combination therapy.
